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Objective. General practitioners’ (GPs’) perception of risk is a cornerstone of preventive care. The aims of this interview study were
to explore GPs’ professional and personal attitudes and experiences regarding treatment with lipid-lowering drugs and their views
on patient compliance.Methods. Thematerial was drawn from semistructured qualitative interviews. We sampled GPs purposively
from ten selected practices, ensuring diversity of demographic, professional, and personal characteristics.TheGPswere encouraged
to describe examples from their own practices and reflect on them and were informed that the focus was their personal attitudes
and experiences. Systematic text condensation was applied for analysis in order to uncover the concepts and themes. Results. The
analysis revealed the following 3 main themes: (1) use of cardiovascular guidelines and risk assessment tools, (2) strategies for
managing patient compliance, and (3) GPs’ own risk management. There were substantial differences in the attitudes concerning
all three themes. Conclusions. The substantial differences in the GPs’ personal and professional risk perceptions may be a key to
understanding why GPs do not always follow cardiovascular guidelines.The impact on daily clinical practice, personal consultation
style, and patient behaviour with regard to prevention is worth studying further.
1. Introduction
Insight into general practitioners’ (GPs) perception of risk is a
cornerstone for understanding their strategies for practicing
preventive care [1, 2]. The way persons perceive risk can be
seen as part of a general personality trait, and healthcare
professionals’ risk perception has impact on their clinical
decision-making [3–5]. Risk perception is influenced by a
mixture of individual considerations, social conditions, and
the specific context [6].
Lipid-lowering drugs are examples of preventive drugs
that can reduce patients’ cardiovascular risk, and specific
clinical guidelines and risk assessment tools and charts have
been developed for use in general practice [7]. However,
differences exist between GPs’ prescribing patterns regarding
lipid-lowering drugs and clinical cardiovascular guidelines
[8–10]. Moreover, patients’ compliance is often low, as
patients do not redeem their prescriptions or do not take
their medication as prescribed [11, 12]. Patient compliance
is an expression of the degree to which the patient decides
to follow a treatment as agreed with the doctor. In some
cases, compliance, adherence, and concordance are perceived
as synonyms; in other cases, the concepts reflect differences
in the doctor-patient relationship and the decision-making
process. Patient compliance has proved to be particularly
low for preventive treatment and for conditions that do not
cause symptoms. Dyslipidaemia itself is not associated with
symptoms, and the reduced blood lipids due to the effect
of lipid-lowering drugs cannot be felt by the patient. The
GP must consider the beneficial effect against the risk of
side effects and take into account the patient’s comedication,
comorbidity, and life expectancy, as well as other patient
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factors, preferences, and the cost of the drug [13, 14]. GP
risk perception can be associated with a broad spectrum
of personal variables such as personality, communication
style, and previous experiences, as well as demographic and
organisational characteristics of the practice. The effect of
the treatment on the individual patient’s risk of developing
cardiovascular disease has been shown to be difficult for
the GP to explain to the patient and a challenge for the
patient to understand [15–17]. Diversity in GPs’ assessment
of cardiovascular risk has been found [1, 18], but their
views and considerations regarding managing dyslipidaemia
and measurement of blood lipids, risk communication, and
personal risk management have not previously been studied.
The aims of this interview study were to explore GPs’ pro-
fessional and personal attitudes and experiences regarding
cardiovascular guidelines and treatment with lipid-lowering
drugs and their views on patient compliance in relation to
medical understanding of risk.
2. Methods
In order to gain a deep insight into the GPs’ perceptions of
cardiovascular risk and compliance, we conducted a quali-
tative study based on semistructured individual interviews
with ten GPs from general practices in the capital and
southern region of Denmark with a combined population
of approximately 2.9 million inhabitants, 1900 GPs, and 1140
practices.
2.1. Sampling. The material was drawn from qualitative in-
depth interviews conducted by the first author, a medi-
cal doctor and Ph.D. student trained for the conduction
of qualitative interviews and completing a comprehensive
course in qualitative research methodology and interview
technique offered by academic experts in social science
and anthropology. Further, all interviews were carefully
supervised by the second and last authors, both experienced
qualitative researchers. We used purposive sampling, where
participants are sampled according to preselected criteria
relevant to the particular research question [19], in this
case both demographic and professional characteristics: we
identified 12 GPs from practices considering the GPs’ age and
gender and their association with single-handed practices,
partnership practices, and practices from rural or urban
areas. These characteristics are known to have an impact on
the management of care and risk perception [3–5]. Thus, the
sample represents experiences from all professional stages of
a GP career from the young and newly established GP to the
GP with more than 30 years of experience, GPs from urban
and remote areas, female and male GPs, and so forth. The 12
GPs were approached: two of the 12 approached GPs did not
respond to our contact and 10 were recruited and interviewed
(Table 1). After 8 interviews no new themes seemed to emerge
and data saturation was assumed to be reached. However, we
chose to carry out the 2 last interviews as initially planned.
2.2. Interview Procedure. The interview guide was developed
on the basis of a literature review and discussions in the
research group comprising clinical pharmacologists, GPs,
Table 1: GP characteristics.
Gender Female 4
Male 6
Age <50 years 3
≥50 years 7
Practice organisation Single-handed GPs 5
Partnership practices 5
Patient recruitment area Rural 4
Urban 6
experts on medical risk analysis, and experienced qualita-
tive researchers. The semistructured and iterative technique
allowed participant responses to affect how and which
questions the interviewer asked next. In that way emerging
themes and perspectives were explored in the interviews with
subsequent participants [20]. The following 4 main topics
were covered in the interviews:management of dyslipidaemia
and measurement of blood lipids, risk communication,
pharmacological prevention, and personal experiences with
cardiovascular risk; see Table 2.
The interviews were carried out from June to November
2013 in the GPs’ practices and took 30–60 minutes each. The
interviewer presented herself as a future GP and researcher
and informed the GPs that they would remain anonymous
and that the interview was part of a larger study on risk
perception and compliance in the research portfolio of the
Research Unit of General Practice.The GPs were encouraged
to describe examples from their own practices and reflect on
them and were informed that the focus was their personal
attitudes and experiences rather than their knowledge of
recommendations and guidelines. The second and the last
author supervised all interviews.
2.3. Analysis. The ten interviews were digitally recorded and
transcribed verbatim by the first author, and all authors
collaborated on the analysis. In order to systematically
uncover important themes and to get a rich straightforward
description of the concepts and latent variables, the explo-
rative approach of systematic text condensation was applied
[21, 22]. The transcripts were read thoroughly to get an
overall impression of the material before the initial coding.
Then, meaning units in each transcript were identified and
the data were coded, sorted, and categorised into themes
and subthemes by identifying similar expressions, patterns,
and sequences. Data from each of the coded groups were
condensed and summarised into generalised descriptions
and concepts concerning views on cardiovascular risk and
views on preventive care. Finally quotes were selected to
illustrate each theme and its related subthemes. During the
analytical process the extracted information was related to
the full transcripts in order not to lose the original context
[21, 23].
3. Results
The analysis of the ten transcripts revealed the follow-
ing 3 main themes: (1) cardiovascular guidelines and risk
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Table 2: Interview guide, probing questions.
Main topics Probing questions
Management of dyslipidaemia and taking
blood lipids
Please tell me about the latest patient you started on lipid-lowering treatment here in the
clinic
Risk communication (i) What is most important to you when you talk to a patient about cardiovascular risk?(ii) How do you use risk assessment tools?
Pharmacological prevention How much importance do you attach to treatment with lipid-lowering drugs?
Personal experiences with cardiovascular risk (i) Do you know your own cholesterol level?(ii) How do you manage your own cardiovascular risk?
Table 3: Summary of results.
Themes Related subthemes Differences in attitudes
Cardiovascular guidelines and
risk assessment tools
Cardiovascular guidelines
(A) Good and applicable, follow them virtually completely
(B) The difference between the academic approach from epidemiological
studies and patients in flesh and blood is challenging
(C) Cardiovascular guidelines inhibit the ability to practice independently
as a GP
Use of risk communication
tools
(A) Not sufficient power in the risk communication
(B) Only for risk assessment, not for risk communication
(C)Thorough use of different tools depending on the patient context
Strategies for managing patient
compliance
Resigned approach (A) Prescribing is the GP’s choice and patients comply(B) Taking preventive drugs is solely the patient’s choice
Confrontational approach (A) Describing consequences of low compliance(B) Revealing barriers to low compliance
Personal risk management
Measuring own blood lipids
(A) Yes, with clear indication
(B) Yes, without clear indication
(C) No, never
Using lipid-lowering drug
themselves
(A) Reluctant
(B) Pragmatic
assessment tools, (2) strategies for managing patient com-
pliance, and (3) GPs’ own risk management. Table 3 and
the following sections summarise the results from the study.
Quotes from the GPs a written in italics below to illustrate
some of the views.
3.1. Cardiovascular Guidelines and Risk Assessment Tools.
The GPs found recommendations and guidelines helpful,
but they chose to make their own medley composed by
the patient’s wishes, preferences, age and polypharmacy, and
adverse effects of the treatment. Further, someGPs stated that
the recommendations lacked different thresholds for different
patient groups and described the conflicts between guidelines
and the laboratories’ thresholds for blood lipids as confusing.
TheGPs expressed the following attitudes towards recom-
mendations and thresholds: some found that the recommen-
dations were helpful as a guide for managing treatment and
stated that they followed them strictly. Othersmentioned that
aspects such as the patient’s age and handling of polyphar-
macy might lead to deviations from the recommendations.
Others again found guideline recommendations based on
epidemiological studies difficult to use in a daily clinical
context with real patients. These GPs were aware of the
recommendations but did not use them actively, and some
even felt that guidelines inhibit practising as a genuine GP.
Some of the reluctance to follow guidelines and recommen-
dations was explained by opposing messages in different
recommendations and a lack of different thresholds for blood
lipids for different groups of patients. Instead someGPsmade
up their own thresholds for initiating preventive treatment.
“Well I just follow them (the recommendations).
I think they are fine, and they help me. They help
me in the sense that we have made a note to put in
the record before the patient comes in. . .to remind
me what questions I should be asking” (Male 64
years, partnership practice).
“They (the patients) can be fitted so much into
charts that there is no room for me to be a doctor
to them. I find that a bit of a problem” (Male 65
years, partnership practice).
The GPs’ attitudes towards and experiences with using
risk assessment tools to assess patients’ cardiovascular risk
and subsequent risk communication varied. Some GPs did
not use risk assessment tools at all and almost felt aversion
to putting patients into charts; others ceased to use them,
as the tools did not provide sufficient support in the com-
munication. A third approach was using the tools solely for
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risk assessment without explicitly involving the patient in the
communication and decision-making.
“Yes, I have used that before, but actually don’t
use it any more. . .. I felt that when I used the
percentages, I didn’t feel it was very helpful.
When I used the general scoring (SCORE) [24],
I often thought they (the patients) weren’t really
in it/didn’t fit into it” (Female 60 years, single-
handed GP).
“. . .I don’t necessarily involve the patient in it,
but it’s just to find out. . .by myself, where we
are” (Male 47 years, partnership practice).
3.2. Strategies for Managing Patient Compliance. The GPs’
strategies for achieving good patient compliance, their com-
munication style, inclination to check patients’ prescription
redemption, and reaction to low compliance varied. Also,
the GPs’ attitudes towards allocation of responsibility of
treatment between the patient and the GP varied. Two
different ways of managing compliance were identified: a
confrontational and a resigned way. In the resigned way,
two different views on where to place the responsibility for
the treatment were represented: compliance was either seen
as the patient’s own choice, which should be respected and
not questioned by the GP, or seen as no problem at all,
since drug treatment is the GP’s choice and the patient is
expected to just comply. In the confrontational group two
different strategies were represented: presenting the patient
with different scenarios of cardiovascular events that might
take place if the drug treatment is not followed and having
repeated consultations to reveal barriers towards following
the agreed treatment.
“I am, after all, a rather paternalistic doctor, so the
patients mostly do what I think and recommend
they should do, without us getting into big and
deep discussions” (Male 65 years, partnership
practice).
“If I feel that (The GP recounts a conversation
between a patient and himself) Patient: ‘Really,
doctor. . .’, GP: ‘Well, okay. You can then see the
nurse, or you can see me once a year. Then we
don’t need to. . .But you are welcome to come back,
if you change your mind. . .and then we have to
be a bit more intensive about your disease. . .For
instance, if you had a stroke’ ” (Male 64 years,
partnership practice).
In Denmark all GPs are able to continuously monitor
patients’ redemption of prescriptions through a national web-
site (https://www.sundhed.dk/). The questions of whether
or not to monitor patients’ prescription redemption showed
considerable diversity: from GPs monitoring patients’
redemptions regularly to GPs considering trust and reliance
on the patient more important than control in order to make
the best decision to GPs rejecting problems with patient
compliance.
“No, not at all, I don’t access sundhed.dk, then I
would feel that I am moving beyond. . .or at least
it is not the type of doctor I want to be, being that
way controlling” (Male 40 years, single-handed
GP).
“I know they do (redeem the prescription)! . . .So
this compliance thing, that’s not a problem, it
really isn’t...” (Male 65 years, single-handedGP).
TheGPs’ reactions to patients with low compliance varied
from just accepting low compliance as the patient’s choice to
irritation to frustration over the time wasted on consultations
and repeated prescription renewals.
“Sometimes with surprise, sometimes with irrita-
tion, and other times I just think that it’s her own
problem” (Male 40 years, single-handed GP).
“Then I get annoyed, because I feel it’s a waste of
my time, just as it is wasting my time to come for
check-up for your diabetes or something else, if you
don’t take themedicine” (Female 56 years, single-
handed GP).
3.3. GPs’ Own Risk Management. The last theme concerned
the GPs’ personal risk management, their attitudes to mea-
suring their own blood lipid level and taking lipid-lowering
drugs themselves. The GPs’ views on measuring their own
blood lipid level varied: from some GPs having measured it if
they had a clear indication to some havingmeasured it several
times out of curiosity without having a clear indication to
others not knowing or caring about their own blood lipids.
The analyses revealed that reluctance towards taking lipid-
lowering drugs exists among GPs. It was expressed that
it could be a big challenge recognising dyslipidaemia as a
problem serious enough to be solved with drugs.
“No way would I consider taking statins, because
I would calculate the same way as for my patients
that I have no reason to fear a cholesterol level
of 7. So it’s a bit on the same rational basis, I
think” (Male 47 years, partnership practice).
“I thought that I just needed to know it (the
cholesterol level), well not because it worried me,
but. . .2005. . .and then I have measured it 7 times
since then, that may be over the top” (Male 65
years, partnership practice).
4. Discussion
This study provides insights to GPs management of cardio-
vascular risk both professionally and personally. It also pro-
vides answers to why GPs may not always follow guidelines
for CVD prevention. Differences in their use of cardiovascu-
lar guidelines and attitudes to assessing and communicating
cardiovascular risk play important roles, as well as their views
of their own cardiovascular risk.
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In the sampling procedure we aimed for a variety in
relevant GP characteristics in order to obtain diversity in the
views on risk perception. However, it cannot be ruled out that
the GPs who agreed to participate may have a bigger interest
in drugs and pharmacotherapy than Danish GPs in general
and therefore our interviews may not have covered the whole
spectrum of views.
The use of only one interviewer may imply both strengths
and weaknesses related to the interviewer’s preconceptions
and special interest in views on cardiovascular risk.
The dialogue with a colleague, the promised anonymity,
and carrying out the interviews in the GP’s own clinic may
have ensured openness and confidentiality. However, some
degree of perceptiveness in the meeting between two clini-
cians could probably not be avoided [25].The role of the inter-
viewer was minimized by broad and critical reading within
the research group consisting of multiple researches with
different backgrounds, that is, clinical pharmacologists, GPs,
and experts on medical risk analysis. Here preconceptions
were shared and discussed, and supplementing and contest-
ing each other’s statements established important metaposi-
tions [22]. This increased the understanding of the complex
phenomena of risk and compliance.
Asking clinicians directly about their professional work
and attitudes towards recommendations and prescribing
practices may have prompted some GPs to give “correct”
and normative answers, more in accordance with clinical
recommendations and guidelines than with their actual
practices and thereby reducing validity [26, 27].TheGPswere
therefore also asked to talk about the most recent patient
they treated with lipid-lowering drugs (Table 2). In this way
the perspectives and approaches towards cardiovascular risk
management were probably concretised and nuanced.
Different approaches to application and implementation
of cardiovascular guidelines were found in the data. From
GPs finding guidelines good and applicable to GPs finding
the process from epidemiological studies and patients in flesh
and blood challenging since it requires too much tailoring to
fit the needs of the individual patient. Other GPs find that
guidelines inhibit the ability to practice independently as a
GP and practice patient centered care. This is in line with
Backlund et al. who found that some GPs explain guideline
deviation with guidelines being too simple in some aspects
[28]. Graversen et al. [9] stated that the gap between rec-
ommended lipid-lowering drug therapy and current practice
causes substantial undertreatment and considerable delay in
the first prescription of lipid-lowering drugs. Both rational
and irrational choices were mentioned as causes for not
following guidelines [29, 30]. Hetlevik et al. [31] pin that GPs
who do not follow practice guidelines may have good reasons
and that it might be an expression of civil disobedience
among particularly ambitious doctors with the best inten-
tions calling for a reassessment of the evidence that guidelines
are based on. Others state that the most important causes
for not following guidelines are unsatisfactory knowledge of
guidelines and barriers to the process of changing clinical
practice in order to implement guidelines. Subjective factors
and individual professional characteristics such as awareness,
knowledge, attitude, motivation to change, and behavioural
mechanisms play an important role [3, 32]. Further, the use
of risk assessment tools and guidelines as well as clinicians’
actual prescribing behaviour may be influenced by such
subjective factors [33]. Future research in concrete actions
to facilitate the transition from clinical guidelines to daily
clinical practice should not only take external and organi-
sational factors into account but also consider differences in
GPs subjective factors and personality traits.
Different approaches also existed in the strategies toman-
age patient compliance with statins. Quite strikingly, some
GPs in the study did not recognise compliance as a potential
issue in clinical practice and expected patients to simply com-
ply with their prescriptions. Others reported to be very con-
cerned about enhancing compliance and revealing potential
barriers. It seemed that younger GPs were more concerned
with enhancing patient compliance than older GPs. This
continuumof approachesmight be related both to differences
in personal communication style and to the paradigm shift
from the classic notion of a paternalistic doctor-patient
relationship to one of shared decision-making and informed
consent—a mutual interactive process between the doctor
and the patient who jointly make a health decision [34].
Although different models to enhance patient compliance
have been suggested [35, 36], the most efficient way for the
GP to address patient compliance is still not fully understood.
The analysis in the present study revealed reluctance
among some GPs towards taking lipid-lowering drugs them-
selves. Yet no informants described problems prescribing
these drugs to their patients and putting effort into enhancing
patient compliance. One of our preconceptions was that the
GPs’ personal risk perception is associatedwith their patients’
behaviour in relation to prevention. Some might fail to see
the relevance of GPs taking blood samples or even statins
themselves to be a measure of how they treat their patients
with elevated blood lipids. It has, however, previously been
shown that doctors personal health habits and beliefs about
counselling [37, 38], as well as personal characteristics [39,
40], strongly influence their practices in counselling patients
about health habits. We recognise that a GP’s prescribing
decision is also the result of many external inputs from the
patient, commercial sources, professional colleagues, the aca-
demic literature, and government regulators [41]. Gale et al.
found striking disconcordance between some GPs’ prescrib-
ing of preventive cardiovascular medication for their patients
and preference of lifestyle changes for themselves [42].This is
in line with the GPs in the present study expressing that they
largely refrain from following the advice on lifestyle they give
their patients. Do the GPs believe that they are less at risk of
cardiovascular disease than their patients, even if they have
the same blood cholesterol level? Might this be an example
of optimistic bias that the GPs and patients have in common
explaining some of the problems with compliance [43]? The
different professional and personal approaches to prevention
among some GPs might also be a sign of the very act of
making a recommendation change the ways GPs think in
relation to medical choice as proposed by Ubel et al. [44].
An analysis of the association between GPs’ professional
and personal views on cardiovascular risk and their actual
behaviour, for example, regarding prescribing patterns for
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lipid-lowering drugs, might be obtained through a quanti-
tative approach using questionnaires in combination with
registers on prescribed and redeemed medication.
5. Conclusion
The substantial differences in the GPs’ personal and pro-
fessional risk perceptions may be a key to understanding
why GPs do not always follow cardiovascular guidelines. The
impact on daily clinical practice, personal consultation style,
and patient behaviour with regard to prevention is worth
studying further.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This work was supported by University of Southern Den-
mark, The Health Foundation, The Committee of Multi-
practice Studies in General Practice, The PLU-Foundation,
and The Danish Heart Foundation. The authors are grateful
to the GPs who participated, to Carl Joachim Brandt for
his assistance with recruitment, and to Lise Keller Stark for
proofreading.
References
[1] J. Nexøe, D. Gyrd-Hansen, J. Kragstrup, I. S. Kristiansen, and J.
B. Nielsen, “Danish GPs’ perception of disease risk and benefit
of prevention,” Family Practice, vol. 19, no. 1, pp. 3–6, 2002.
[2] P. Kirkegaard, M. B. Risor, A. Edwards, A. G. Junge, and J. L.
Thomsen, “Speaking of risk, managing uncertainty: decision-
making about cholesterol-reducing treatment in general prac-
tice,” Quality in Primary Care, vol. 20, no. 4, pp. 245–252, 2012.
[3] J. J. Rolison, Y. Hanoch, S. Wood, and P.-J. Liu, “Risk-taking
differences across the adult life span: a question of age and
domain,” Journals of Gerontology B Psychological Sciences and
Social Sciences, vol. 69, no. 6, pp. 870–880, 2014.
[4] D. N. Jackson, L. Hourany, and N. J. Vidmar, “A four-
dimensional interpretation of risk taking,” Journal of Personal-
ity, vol. 40, no. 3, pp. 483–501, 1972.
[5] D. R. Holtgrave, F. Lawler, and S. J. Spann, “Physicians’ risk
attitudes, laboratory usage, and referral decisions: the case of
an academic family practice center,” Medical Decision Making,
vol. 11, no. 2, pp. 125–130, 1991.
[6] D. Kahneman and A. Tversky, “Prospect theory: an analysis of
decision under risk,” Econometrica, vol. 47, no. 2, pp. 263–291,
1979.
[7] B. F. O. Christensen, N. C. Heebøll-Nielsen, J. Lous, L. D.
Madsen, and S. Stender, “Prevention of cardiovascular disease
in general practice in Danish,” in Clinical Guideline, Danish
College of General Practicioners, Copenhagen, Denmark, 3rd
edition, 2007.
[8] M. Di Martino, L. Degli Esposti, P. Ruffo et al., “Underuse of
lipid-lowering drugs and factors associated with poor adher-
ence: a real practice analysis in Italy,” European Journal of
Clinical Pharmacology, vol. 61, no. 3, pp. 225–230, 2005.
[9] L. Graversen, B. Christensen, K. Borch-Johnsen, T. Lauritzen,
and A. Sandbaek, “General practitioners’ adherence to guide-
lines onmanagement of dyslipidaemia:ADDITION-Denmark,”
Scandinavian Journal of Primary Health Care, vol. 28, no. 1, pp.
47–54, 2010.
[10] Z. Reiner, A. L. Catapano, G. De Backer et al., “ESC/EAS guide-
lines for the management of dyslipidaemias: the task force for
the management of dyslipidaemias of the European Society of
Cardiology (ESC) and the European Atherosclerosis Society
(EAS),” European Heart Journal, vol. 32, no. 14, pp. 1769–1818,
2011.
[11] A. Pottega˚rd, R. D. Christensen, A. Houji et al., “Primary non-
adherence in general practice: a danish register study,”European
Journal of Clinical Pharmacology, vol. 70, no. 6, pp. 757–763,
2014.
[12] E. Sabate´, Adherence to Long-Term Therapies: Evidence for
Action, WHO Library Cataloguing-in-Publication Data, 2003.
[13] F. Vancheri, L.-E. Strender, and L. G. Backlund, “General
Practitioners’ coronary risk estimates, decisions to start lipid-
lowering treatment, gender and length of clinical experience:
their interactions in primary prevention,” Primary health care
research & development, vol. 14, no. 4, pp. 394–402, 2013.
[14] R. Madanieh, R. K. Hasan, O. F. Anusionwu, R. S. Blumenthal,
and M. J. Blaha, “Cardiovascular disease prevention: matching
evidence-based algorithms with individualized care,” Clinical
Pharmacology &Therapeutics, vol. 93, no. 4, pp. 321–323, 2013.
[15] P. Lytsy, G. Burell, and R. Westerling, “How do prescribing
doctors anticipate the effect of statins?” Journal of Evaluation
in Clinical Practice, vol. 17, no. 3, pp. 420–428, 2011.
[16] L. K. H. Felde, Identity work among people with elevated choles-
terol: the every day elasticity of compliance withmedical regimens
[Ph.D. thesis], Aarhus University, Aarhus, Denmark, 2010.
[17] T. A. Geest, M. Engberg, and T. Lauritzen, “Discordance
between self-evaluated health and doctor-evaluated health in
relation to general health promotion,” Scandinavian Journal of
Primary Health Care, vol. 22, no. 3, pp. 146–151, 2004.
[18] P. A. Halvorsen, I. S. Kristiansen, O. G. Aasland, and O. H.
Førde, “Medical doctors’ perception of the ‘number needed to
treat’ (NNT): a survey of doctors’ recommendations for two
therapies with different NNT,” Scandinavian Journal of Primary
Health Care, vol. 21, no. 3, pp. 162–166, 2003.
[19] N. Mack, C. Woodsong, K. Macqueen, G. Guest, and E. Namey,
Qualitative Research Methods: A Data Collector’s Field Guide,
Family Health International, USAID, 2005.
[20] S. Kvale, InterView, Hans Reitzels Forlag A/S, Copenhagen,
Denmark, 2004.
[21] K. Malterud, “Systematic text condensation: a strategy for
qualitative analysis,” Scandinavian Journal of Public Health, vol.
40, no. 8, pp. 795–805, 2012.
[22] K. Malterud, “Qualitative research: standards, challenges, and
guidelines,”The Lancet, vol. 358, no. 9280, pp. 483–488, 2001.
[23] M. Sandelowski, “Whatever happened to qualitative descrip-
tion?” Research in Nursing and Health, vol. 23, no. 4, pp. 334–
340, 2000.
[24] J. Perk, G. De Backer, H. Gohlke et al., “European guidelines
on cardiovascular disease prevention in clinical practice (ver-
sion 2012). the fifth joint task force of the European society
of cardiology and other societies on cardiovascular disease
prevention in clinical practice (constituted by representatives of
nine societies and by invited experts),” European Heart Journal,
vol. 33, no. 13, pp. 1635–1701, 2012.
International Journal of Family Medicine 7
[25] H.-G. Gadamer, Truth and Method, Bloomsbury Academic,
London, UK, 1993.
[26] G. T. Yeo, S. P. H. de Burgh, T. Letton et al., “Educational visit-
ing and hypnosedative prescribing in general practice,” Family
Practice, vol. 11, no. 1, pp. 57–61, 1994.
[27] J. W. Beckstead, M. V. Pezzo, T. M. Beckie, F. Shahraki, A.
C. Kentner, and S. L. Grace, “Physicians’ tacit and stated
policies for determining patient benefit and referral to cardiac
rehabilitation,” Medical Decision Making, vol. 34, no. 1, pp. 63–
74, 2014.
[28] L. Backlund, Y. Skaner, H. Montgomery, J. Bring, and L.-E.
Strender, “The role of guidelines and the patient’s life-style
in GPs’ management of hypercholesterolaemia,” BMC Family
Practice, vol. 5, article 3, 2004.
[29] P. Midlo¨v, R. Ekesbo, L. Johansson et al., “Barriers to adherence
to hypertension guidelines among GPs in southern Sweden: a
survey,” Scandinavian Journal of Primary Health Care, vol. 26,
no. 3, pp. 154–159, 2008.
[30] E. Ab, P. Denig, T. Van Vliet, and J. H. Dekker, “Reasons of
general practitioners for not prescribing lipid-loweringmedica-
tion to patients with diabetes: a qualitative study,” BMC Family
Practice, vol. 10, article 24, 2009.
[31] I. Hetlevik, L. Getz, and A. L. Kirkengen, “General practitioners
who do not follow practice guidelines—may they have reasons
not to?” Tidsskrift for Den norske legeforening, vol. 128, no. 19,
pp. 2218–2220, 2008.
[32] R. Grol and M. Wensing, “What drives change? Barriers to
and incentives for achieving evidence-based practice,” Medical
Journal of Australia, vol. 180, no. 6, supplement, pp. S57–S60,
2004.
[33] S. Greenfield, S. Bryan, P. Gill, K. Gutridge, and T. Marshall,
“Factors influencing clinicians’ decisions to prescribe medi-
cation to prevent coronary heart disease,” Journal of Clinical
Pharmacy andTherapeutics, vol. 30, no. 1, pp. 77–84, 2005.
[34] A. Edwards and G. Elwyn, Shared Decision-Making in Health
Care: Achieving Evidence-Based Patient Choice, Oxford Univer-
sity Press, 2009.
[35] T. S. Barfod, F. M. Hecht, C. Rubow, and J. Gerstoft, “Physicians’
communication with patients about adherence to HIVmedica-
tion in San Francisco andCopenhagen: a qualitative study using
GroundedTheory,” BMCHealth Services Research, vol. 6, article
154, 2006.
[36] S. M. Cohen, “Concept analysis of adherence in the context of
cardiovascular risk reduction,”Nursing Forum, vol. 44, no. 1, pp.
25–36, 2009.
[37] K. B. Wells, C. E. Lewis, B. Leake, and J. E. Ware Jr., “Do
physicians preach what they practice? A study of physicians’
health habits and counseling practices,” Journal of the American
Medical Association, vol. 252, no. 20, pp. 2846–2848, 1984.
[38] O. Y. Hung, N. L. Keenan, and J. Fang, “Physicians’ health
habits are associated with lifestyle counseling for hypertensive
patients,” American Journal of Hypertension, vol. 26, no. 2, pp.
201–208, 2013.
[39] M. A. Smith, E. D. Cox, and J. M. Bartell, “Overprescribing of
lipid lowering agents,” Quality & Safety, vol. 15, no. 4, pp. 251–
257, 2006.
[40] A. Rashidian and I. Russell, “Intentions and statins prescrib-
ing: can the theory of planned behaviour explain physician
behaviour in following guideline recommendations?” Journal of
Evaluation in Clinical Practice, vol. 17, no. 4, pp. 749–757, 2011.
[41] S. B. Soumerai, T. J. McLaughlin, and J. Avorn, “Improving
drug prescribing in primary care: a critical analysis of the
experimental literature,” Milbank Quarterly, vol. 67, no. 2, pp.
268–317, 1989.
[42] N. K. Gale, S. Greenfield, P. Gill, K. Gutridge, and T. Marshall,
“Patient and general practitioner attitudes to taking medication
to prevent cardiovascular disease after receiving detailed infor-
mation on risks and benefits of treatment: a qualitative study,”
BMC Family Practice, vol. 12, article 59, 2011.
[43] T. Sharot, A. M. Riccardi, C. M. Raio, and E. A. Phelps, “Neural
mechanisms mediating optimism bias,” Nature, vol. 450, no.
7166, pp. 102–105, 2007.
[44] P. A. Ubel, A. M. Angott, and B. J. Zikmund-Fisher, “Physicians
recommend different treatments for patients than they would
choose for themselves,” Archives of Internal Medicine, vol. 171,
no. 7, pp. 630–634, 2011.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
